Reference ranges
Optimal ranges are tighter than standard lab ranges and reflect functional-medicine targets, not the populations they were derived from. Reference bands depend on sex, age, and circumstance — Juno's lab analysis layers your profile context onto the printed range when you paste a value.
Peptide relevance
Standard cardiovascular risk marker; targets depend on individual risk profile (lower for established CVD or familial hypercholesterolemia). GLP-1 agonists (tirzepatide, semaglutide) modestly lower LDL-C (~3-7% in trials, driven mostly by weight loss). CJC-1295 + Ipamorelin: GH axis activation can transiently raise LDL during the first weeks; longer-term effect is usually neutral or favorable as body composition improves. BPC-157 / TB-500: no documented effect. Anabolic-androgenic steroids (NOT peptides, sometimes co-used) often lower HDL and raise LDL. NOTE: Lp(a) and ApoB are more granular CV risk markers — track those when LDL is borderline or family history is concerning.
Peptides that influence this marker
Documented to affect this marker. Click through for the full evidence-tiered profile.
Have a recent LDL cholesterol (LDL-C) value?
Paste it on the lab analysis page. Juno reads your active stack + (if shared) your medications and conditions, and surfaces plausible contributors with citations. Doesn't diagnose.
Sign-in required. The analysis is saved to your private history and audit-logged.